At the center of the current legal battle over abortion is telehealth access to one drug, Mithapristone.

Since the Supreme Court overturned Roe v. Wade in 2022, Miffa Pristone has become the dominant

method of abortion in the United States,

filling the gap left by clinic closures in states with abortion bans. And the number of abortions

has actually risen slightly in the years since Roe was overturned. That's a problem for abortion

opponents. And they're taking aim at one of the main ways Miphypristo is prescribed via telehealth.

Last week, they scored their first big win. In response to a Louisiana lawsuit, a federal appeals

court blocked Miphaepristone from being prescribed virtually or mailed to patients. The

drugs manufacturers challenged the decision, and this week the Supreme Court temporarily restored

telehealth access while it considers the case. That stay expires Monday and briefs from both sides

are due today. If the lower court's decision is upheld, it could upend how abortions are provided

in the U.S., ending telehealth access for people in states with bans, and making it

harder to access even in states where abortion is legal. It could also limit access to the drug for

people using it for miscarriage care. I'm Jen White. You're listening to the 1A podcast. Today we ask,

what's next in the legal and political battle and what does it all mean for patients and

reproductive health providers. We'll be back with more after this short break. Stay with us.

Welcome back to the 1A podcast. We're talking about telehealth access to Mifapristone, a drug

commonly used in abortions and miscarriage care.

Joining us from here in D.C. is Shafali Luthera. She covers reproductive health for the 19th news.

She's also the author of Undue Burden, Life and Death Decisions in Post-Roe America.

Thank you so much for having me.

And we want to hear from you. If you've had a miscarriage or abortion, did you use telemedicine to get Mithipristone?

...